I am not trying to hang a pall over this discussion but for the sake of disclosure and keeping to reality I will reveal this. It is often referred to here that a shrinking number of MACE events other than to causes like fewer patients left in dosing, etc. is good news as it must be that Apabetalone is working well. I have once been the victim of a trial where the dosed group performed as expected but the placebo group performed way above expectations with the result that the trial was not statiscally successful. Just another possibility that I truly hope is not true and probably isn't but belongs in the mix for consideration.